Relating to drugs and adding a provision relating to the scheduling of crystalline polymorph psilocybin approved by the Food and Drug Administration

This bill amends West Virginia's drug scheduling laws to allow the legal prescription, distribution, and marketing of crystalline polymorph psilocybin if it receives FDA approval and DEA rescheduling. The legislation specifically targets this particular form of psilocybin, which is a type of psychedelic compound, and would permit its use under federal regulatory frameworks. The bill requires the state Board of Pharmacy to align West Virginia's controlled substance schedules with federal actions regarding this specific psilocybin variant. It does not change the scheduling status of other drugs or expand access to psilocybin beyond the specific FDA-approved crystalline polymorph form. The measure affects healthcare providers, pharmacies, and patients who might access this substance through approved medical channels.